aponvie (aprepitant) has been made available by Heron Therapeutics for the prevention of postoperative nausea and vomiting in adults.
Aponvie is an injectable emulsion formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. The formulation is identical to Heron’s approved drug product Cinvanti®, which is indicated for chemotherapy induced nausea and vomiting.
The safety and efficacy of Aponvie were established based on adequate and well-controlled studies of a single dose of oral aprepitant in adults. Additionally, a single 32mg dose of Aponvie was found to be bioequivalent to oral aprepitant 40mg in a phase 1 study.
Aponvie is supplied in a single-dose vial containing 32mg of aprepitant.
Related Content
